Promising new eye treatment could halt vision loss from keratoconus
NCT ID NCT06100952
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tested a new type of corneal cross-linking that does not require removing the surface layer of the eye. It involved 398 people aged 8 to 45 with keratoconus, a condition that thins and bulges the cornea. The treatment uses riboflavin eye drops and ultraviolet light to strengthen the cornea and stop the disease from progressing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Riboflavin and sodium iodide eye drops plus ultraviolet-A light treatment
What this could lead to
If successful, this could offer a less painful, faster-recovery treatment to stop keratoconus from getting worse and improve vision.
What could go wrong
This is a phase 3 trial, but results are not yet published. The treatment may not work better than a sham procedure, and there are risks like infection or corneal scarring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KERATOCONUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Catalina Eye Center
Tucson, Arizona, 85712, United States
-
Chicago Cornea Consultants
Highland Park, Illinois, 60035, United States
-
Claris Vision LLC Eye Health Vision Centers - Dartmouth
North Dartmouth, Massachusetts, 02747, United States
-
Dell Laser Consultants
Austin, Texas, 78746, United States
-
Hoopes Vision
Draper, Utah, 84020, United States
-
Inland Eye Specialists
Murrieta, California, 92562, United States
-
Providence Eye and Laser Specialists
Charlotte, North Carolina, 28226, United States
-
Schwartz Laser Eye Center
Scottsdale, Arizona, 85260, United States
-
Truhlsen Eye Institute
Omaha, Nebraska, 68105, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
VRF Eye Specialty Group
Memphis, Tennessee, 38120, United States
-
Virginia Eye Consultants
Norfolk, Virginia, 23502, United States